Human Genome Project and Cardiovascular Disease Genes

Molecular Basis of Cardiovascular Disease: A Companion to Braunwald's Heart Disease

Volumn , Issue , 2004, Pages 16-38

  Liew, Choong Chin ^a,b,c   Dzau, Victor J ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 26844445466     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7216-9428-3.50007-X     Document Type: Chapter

References (200)

1. Lander E, Weinberg RA Genomics: Journey to the center of biology. Science 2000, 287:1777-1782.
2. Service RF Big biology is bad biology. Science 2001, 291:1182.
3. Collins FS, McKusik VA Implications of the human genome project for medical science. JAMA 2001, 285:540-544.
4. Department of Health and Human Services and Department of Energy Understanding Our Genetic Inheritance. The US Human Genome Project: The First Five Years: 1991-1995 1990, Government Printing Office, Washington DC, (NIH publication #90-1590).
5. Collins FS Medical and societal consequences of the human genome project. N Engl J Med 1999, 341:28-37.
6. Altschul SF, Gish W, Miller W, et al. Basic local alignment search tool. J Mol Biol 1990, 215:403-410.
7. Adams MD, Kelley JM, Gocayne JD, et al. Complementary DNA sequencing: Expressed sequence tags and the human genome project. Science 1991, 252:1651-1656.
8. Vollrath D, Foote S, Hilton A, et al. The human Y chromosome: A 43-interval map based on naturally occurring deletions. Science 1992, 258:52-59.
9. Chumakov I, Rigault P, Guillou S, et al. Continuum of overlapping clones spanning the entire human chromosome 21q. Nature 1992, 359:380-387.
10. Dietrich W, Katz H, Lincoln SE, et al. A genetic map of the mouse suitable for typing intraspecific crosses. Genetics 1992, 131:423-447.
11. Cohen D, Chumakov I, Weissenback J A first generation physical map of the human genome. Nature 1993, 366:698-701.
12. Collins F, Galas D A new five-year plan for the U.S. Human Genome Project. Science 1993, 262:43-46.
13. Fleischmann RD, Adams MD, White O, et al. Whole-genome random sequencing and assembly of Haemophilus influenzae. Science 1995, 269:496-512.
14. Hudson T, Stein LD, Gerety SS, et al. An STS-based map of the human genome sequence. Science 1995, 270:1945-1954.
15. Clayton RA, White O, Ketchum KA, et al. The first genome from the third domain of life. Nature 1997, 387:459-462.
16. The C elegans Sequencing Consortium Genome sequence of the nematode C. elegans: A platform for investigating biology. Science 1998, 282:2012-2018.
17. Bentley DR Genomic sequence information should be released immediately and freely in the public domain. Science 1996, 274:533-534.
18. Macilwain C World leaders heap praise on human genome landmark. Nature 2000, 405:983-984.
19. Brown K The Human genome business today. Sci Am 2000, 283:50-55.
20. Collins FS, Patrinos A, Jordan E, et al. New goals for the US human genome project: 1998-2003. Science 1998, 282:682-689.
21. Venter JC, Adams MD, Myers EW The sequence of the human genome. Science 2001, 291:1304-1351.
22. Genome Sequencing Consortium Initial sequencing and analysis of the human genome. Nature 2001, 409:860-921.
23. Jasny B, Kennedy D The human genome. Science 2001, 291:1153.
24. Pennisi E The human genome. Science 2001, 291:1177-1180.
25. http://www.ornl.gov/TechResources/Human_Genome/faq/genenumber.html.
26. Dempsey AA, Dzau VJ, Liew CC Cardiovascular genomics: Estimating the total number of genes expressed in the human cardiovascular system. J Mol Cell Cardiol 2001, 33:1879-1886.
27. Adams MD, Kelley JM, Gocayne JD, et al. Complementary DNA sequencing: Expressed sequence tags and human genome project. Science 1991, 252:1651-1656.
28. Putney SD, Herlihy WC, Schimmel P A new troponin T and cDNA clones for 13 different muscle proteins, found by shotgun sequencing. Nature 1983, 302:718-721.
29. Roberts L Gambling on a shortcut to genome sequencing. Science 1991, 252:1618-1619.
30. Liew CC A human heart cDNA library-the development of an efficient and simple method for automated DNA sequencing. J Mol Cell Cardiol 1993, 25:891-894.
31. Liew CC, Hwang DM, Fung YW, et al. A catalogue of genes in the cardiovascular system as identified by expressed sequence tags (ESTs). Proc Natl Acad Sci USA 1994, 91:10645-10649.
32. Hwang DM, Dempsey AA, Wang RX, et al. A genome-based resource for molecular cardiovascular medicine: Toward a compendium of cardiovascular genes. Circulation 1997, 96:4146-4203.
33. Roberts L Genome patent fight erupts. Science 1991, 254:184-186.
34. Marshall E The company that genome researchers love to hate. Science 1994, 266:1800-1802.
35. Adams MD, Dubnick M, Kerlavage AR Sequence identification of 2,375 human brain genes. Nature 1992, 355:632-634.
36. Adams MD, Kerlavage AR, Fields C, Venter JC 3,400 new expressed sequence tags identify a diversity of transcripts in human brain. Nat Genet 1993, 4:256-267.
37. Adams MD, Soares MB, Kerlavage AR, et al. Rapid cDNA sequencing (expressed sequence tags) from a directionally cloned human infant brain cDNA library. Nat Genet 1993, 4:373-380.
38. Hwang DM, Hwang WS, Liew CC Single pass sequencing of a unidirectional human fetal heart cDNA library to discover novel genes of the cardiovascular system. J Mol Cell Cardiol 1994, 26:1329-1333.
39. Sudo K, Chinen K, Nakamura Y 2058 Expressed sequence tags (ESTs) from a human fetal lung cDNA library. Genomics 1994, 24:276-279.
40. Schmidtke J, Cooper DN A comprehensive list of cloned human DNA sequences-1990 update. Nucleic Acids Res 1991, 19:2111-2126. (Suppl.).
41. Miller G, Fuchs R, Lai E IMAGE cDNA clones, UniGene clustering, and ACeDB: An integrated resource for expressed sequence information. Genome Res 1997, 7:1027-1032.
42. Boguski MS, Lowe TM, Tolstoshev CM dbEST: A database of expressed sequence tags. Nat Genet 1993, 4:332-333.
43. Ton C, Hwang DM, Dempsey AA, et al. Identification, characterization and mapping of expressed sequence tags from an embryonic zebrafish heart cDNA library. Genome Res 2000, 10:1915-1927.
44. Okubo K, Hori N, Matoba R, et al. Large scale cDNA sequencing for analysis of quantitative and qualitative aspects of gene expression. Nat Genet 1992, 2:173-179.
45. Adams MD, Kerlavage AR, Fleischmann RD, et al. Initial assessment of human gene diversity and expression patterns based upon 83 million nucleotides of cDNA sequence. Nature 1995, 377:3-174. (Suppl.).
46. Hwang DM, Fung YW, Wang RX, et al. Analysis of expressed sequence tags from a fetal human heart cDNA library. Genomics 1995, 30:293-298.
47. Bortoluzzi S, d'Alessi F, Danieli GA A novel resource for the study of genes expressed in the adult human retina. Invest Ophthalmol Vis Sci 2000, 41:3305-3308.
48. Ji H, Liu YE, Jia T, et al. Identification of a breast cancer-specific gene, BCSG1, by direct differential cDNA sequencing. Cancer Res 1997, 57:759-764.
49. Levy-Lahad E, Wasco W, Poorkaj P, et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 1995, 269:973-977.
50. Banfi S, Borsani G, Rossi E, et al. Identification and mapping of human cDNAs homologous to Drosophila mutant genes through EST database searching. Nat Genet 1996, 13:167-174.
51. Miklos GL, Rubin GM The role of the genome project in determining gene function: Insights from model organisms. Cell 1996, 86:521-529.
52. Rawlings CJ, Searls DB Computational gene discovery and human disease. Curr Opin Genet Dev 1997, 7:416-423.
53. Papadopoulos N, Nicolaides NC, Wei YF, et al. Mutation of a mutL homolog in hereditary colon cancer. Science 1994, 263:1625-1629.
54. Sargent CA, Affara NA, Bentley E, et al. Cloning of the X-linked glycerol kinase deficiency gene and its identification by sequence comparison to the Bacillus subtilis homologue. Hum Mol Genet 1993, 2:97-106.
55. Banfi S, Borsani G, Rossi E, et al. Identification and mapping of human cDNAs homologous to Drosophila mutant genes through EST database searching. Nat Genet 1996, 13:167-174.
56. Banfi S, Borsani G, Bulfone A, Ballabio A Drosophila-related expressed sequences. Hum Mol Genet 1997, 6:1745-1753.
57. Bassett DE, Boguski MS, Spencer F, et al. Genome cross-referencing and XREFdb: Implications for the identification and analysis of genes mutated in human disease. Nat Genet 1997, 15:339-344.
58. Schena M, Shalon D, Davis RW, et al. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995, 270:467-470.
59. Velculescu VE, Zhang L, Vogelstein B, Kinzler KW Serial analysis of gene expression. Science 1995, 270:484-487.
60. de Waard V, van den Berg BM, Veken J, et al. Serial analysis of gene expression to assess the endothelial cell response to an atherogenic stimulus. Gene 1999, 226:1-8.
61. Lockhart DJ, Dong H, Byrne MC, et al. Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat Biotechnol 1996, 14:1675-1680.
62. Bowtell DDL Options available-from start to finish-for obtaining expression data by microarray. Nat Genet Suppl 1999, 21:25-32.
63. Lipshutz RJ, Fodor SPA, Gingeras TR, et al. High density synthetic oligonucleotide arrays. Nat Genet Suppl 1999, 21:20-24.
64. DeRisi J, Penland L, Brown PO, et al. Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat Genet 1996, 14:457-460.
65. Perou CM, Jeffrey SS, vandeRinj M, et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA 1999, 96:9212-9217.
66. Eisen MB, Spellman PT, Brown PO, Botstein D Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998, 95:14863-14868.
67. Iyer VR, Eisen MB, Ross DT, et al. The transcriptional program in the response of human fibroblasts to serum. Science 1999, 283:83-87.
68. Barrans JD, Stamatiou D, Liew CC Construction of a human cardiovascular cDNA microarray: Portrait of a failing heart. Biochem Biophys Res Commun 2001, 280:964-969.
69. Hwang JJ, Dzau VJ, Liew CC Genomics and the pathophysiology of heart failure. Curr Cardiol Rep 2001, 3:198-207.
70. Friddle CL, Koga T, Rubin EM, Bristo J Expression profiling reveals distinct sets of genes altered during induction and regression of cardiac hypertrophy. PNAS 2000, 97:6745-6750.
71. Yang J, Moravec CS, Sussman MA Decreased SLIM1 expression and increased gelsolin expression in failing human hearts measured by high-density oligonucleotide arrays. Circulation 2000, 102:3046-3052.
72. Barrans JD, Sc MH, Allen PD, et al. Global gene expression profiling of end stage dilated cardiomyopathy using a human cardiovascular based cDNA microarray. Am J Pathol 2002, 160:2035-2043.
73. Towbin JA, Bowles NE Genetic abnormalities responsible for dilated cardiomyopathy. Curr Cardiol Rep 2000, 2:475-480.
74. Towbin JA The role of cytoskeletal proteins in cardiomyopathies. Curr Opin Cell Biol 1998, 10:131-139.
75. Elliott K, Watkins H, Redwood CS Altered regulatory properties of human cardiac troponin I mutants that cause hypertrophic cardiomyopathy. J Biol Chem 2000, 275:22069-22074.
76. Kimura A, Harada H, Park JE, et al. Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy. Nat Genet 1997, 16:379-382.
77. Redwood C, Lohmann K, Bing W, et al. Investigation of a truncated cardiac troponin T that causes familial hypertrophic cardiomyopathy: Ca(2+) regulatory properties of reconstituted thin filaments depend on the ratio of mutant to wild-type protein. Circ Res 2000, 86:1146-1152.
78. Geisterfer-Lowrance AA, Kass S, Tanigawa G A molecular basis for familial hypertrophic cardiomyopathy: A beta cardiac myosin heavy chain gene missense mutation. Cell 1990, 62:999-1006.
79. Thierfelder L, Watkins H, MacRae C, et al. Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: A disease of the sarcomere. Cell 1994, 77:701-712.
80. Dalakas MC, Park KY, Semino-Mora C, et al. Desmin myopathy, a skeletal myopathy with cardiomyopathy caused by mutations in the desmin gene. N Engl J Med. 2000, 342:770-780.
81. Satoh M, Takahashi M, Sakamoto T, et al. Structural analysis of the titin gene in hypertrophic cardiomyopathy: Identification of a novel disease gene. Biochem Biophys Res Commun 1999, 262:411-417.
82. Schonberger J, Seidman CE Many roads lead to a broken heart: The genetics of dilated cardiomyopathy. Am J Hum Genet 2001, 69:249-260.
83. Olson TM, Michels VV, Thibodeau SN, et al. Actin mutations in dilated cardiomyopathy, a heritable form of heart failure. Science 1998, 280:750-752.
84. Arber S, Hunter JJ, Ross J, et al. MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure. Cell 1997, 88:393-403.
85. Dempsey AA, Ton C, Liew CC A cardiovascular EST repertoire: Progress and promise for understanding cardiovascular disease. Mol Med Today 2000, 6:231-237.
86. Francis GS Changing the remodeling process in heart failure: Basic mechanisms and laboratory results. Curr Opin Cardiol 1998, 13:156-161.
87. Rao VU, Spinale FG Controlling myocardial matrix remodeling: Implications for heart failure. Cardiol Rev 1999, 7:136-143.
88. McKinsey TA, Olson EN Cardiac hypertrophy: Sorting out the circuitry. Curr Opin Genet Dev 1999, 9:267-274.
89. Chien KR Genomic circuits and the integrative biology of cardiac diseases. Nature 2000, 407:227-232.
90. Miyamoto MI, del Monte F, Schmidt U, et al. Adenoviral gene transfer of SERCA2a improves left ventricular function in aortic-banded rats in transition to heart failure. Proc Natl Acad Sci 2000, 97:793-798.
91. Tada M, Yabuki M, Toyofuku T Molecular regulation of phospho-lamban function and gene expression. Ann NY Acad Sci 1998, 853:116-129.
92. Marks AR Cardiac intracellular calcium release channels: Role in heart failure. Circ Res 2000, 87:8-11.
93. Dewaste V, Pouillon V, Moreau C, et al. Cloning and expression of a cDNA encoding human inositol 1,4,5-trisphosphate 3-kinase C. Biochem J 2000, 352:343-351.
94. Pyeritz RE Genetic approaches to cardiovascular disease. Molecular Basis of Cardiovascular Disease: A Companion to Braunwald's Heart Disease 1999, 19-36. WB Saunders, Philadelphia. K. Chien (Ed.).
95. Uddhav K, Ketan S Advances in the human genome project. Mol Biol Rep 1998, 25:27-43.
96. Collins FS Positional cloning: Lets not call it reverse any more. Nat Genet 1992, 1:3-6.
97. Royer-Pokora B, Kunkel LM, Monaco AP, et al. Cloning the gene for an inherited human disorder, chronic granulomatous disease, on the basis of its chromosomal location. Nature 1986, 322:32-38.
98. Collins FS Positional cloning moves from perditional to traditional. Nat Genet 1995, 9:347-350.
99. Teare D Asymmetrical hypertrophy of the heart in young patients. Br Heart J 1958, 20:1-8.
100. Jarcho JA, McKenna W, Pare JA, et al. Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14Q2. N Engl J Med 1989, 321:1372-1378.
101. Watkins H, MacRae C, Thierfelder L, et al. A disease locus for familial hypertrophic cardiomyopathy maps to chromosome 1q3. Nat Genet 1993, 3:333-337.
102. Thierfelder L, MacRae C, Watkins H, et al. A familial hypertrophic cardiomyopathy locus maps to chromosome 15q2. Proc Natl Acad Sci USA 1993, 90:6270-6274.
103. Ferrari P, Bianchi G Genomics of cardiovascular disorders. Drugs 2000, 59:1025-1042.
104. Bonne G, Carrier L, Richard P, et al. Familial hypertrophic cardiomyopathy from mutations to functional defects. Circ Res 1998, 83:580-593.
105. Marian AJ, Roberts R Molecular genetic basis of hypertrophic cardiomyopathy: Genetic markers for sudden cardiac death. J Cardiovasc Electrophysiol 1998, 9:88-99.
106. Milewicz D, Seidman CE Genetics of cardiovascular disease. Circulation 2000, 102:103-111.
107. Kamisago M, Sharma SD, DePalma SR, et al. Mutations on sarcomere protein genes as a cause of dilated cardiomyopathy. N Engl J Med 2000, 343:1688-1696.
108. Li D, Tapscoft T, Gonzalez O, et al. Desmin mutation responsible for idiopathic dilated cardiomyopathy. Circulation 1999, 100:461-464.
109. Campbell KP Three muscular dystrophies: Loss of cytoskeleton-extracellular matrix linkage. Cell 1995, 80:675-679.
110. Muntoni F, Wilson L, Marrosu G, et al. A mutation in the dystrophin gene selectively affecting dystrophin expression in the heart. J Clin Invest 1995, 96:693-699.
111. Brodsky GL, Muntoni F, Miocic S, et al. Lamin A/C gene mutation associated with dilated cardiomyopathy with variable skeletal muscle involvement. Circulation 2000, 101:473-476.
112. Fatkin D, MacRae C, Sasaki T, et al. Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N Engl J Med 1999, 341:1715-1724.
113. Mathur A, Sims HF, Gopalakrishnan D, et al. Molecular heterogeneity in very-long-chain acyl-CoA dehydrogenase deficiency causing pediatric cardiomyopathy and sudden death. Circulation 1999, 99:1337-1343.
114. McConnell BK, Jones KA, Fatkin D, et al. Dilated cardiomyopathy in homozygous myosin-binding protein-C mutant mice. J Clin Invest 1999, 104:1235-1244.
115. Sakamoto A, Ono K, Abe M, et al. Both hypertrophic and dilated cardiomyopathies are caused by mutation of the same gene, delta-sarcoglycan, in hamster: An animal model of disrupted dystrophin-associated glycoprotein complex. Proc Natl Acad Sci USA 1997, 94:13873-13878.
116. Chien KR Stress pathways and heart failure. Cell 1999, 98:555-558.
117. Mende U, Kagen A, Cohen A, et al. Transient cardiac expression of constitutively active Galphaq leads to hypertrophy and dilated cardiomyopathy by calcineurin-dependent and independent pathways. Proc Natl Acad Sci USA 1998, 95:13893-13898.
118. Fentzke RC, Korcarz CE, Lang RM, et al. Dilated cardiomyopathy in transgenic mice expressing a dominant-negative CREB transcription factor in the heart. J Clin Invest 1998, 101:2415-2426.
119. Kubota T, McTiernan CF, Frye CS, et al. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res 1997, 81:627-635.
120. Subbarayan V, Mark M, Messadeq N, et al. RXRalpha overexpression in cardiomyocytes causes dilated cardiomyopathy but fails to rescue myocardial hypoplasia in RXRalpha-null fetuses. J Clin Invest 2000, 105:387-394.
121. Emanueli C, Maestri R, Corradi D, et al. Dilated and failing cardiomyopathy in bradykinin B(2) receptor knockout mice. Circulation 1999, 100:2359-2365.
122. Sussman MA, Welch S, Cambon N, et al. Myofibril degeneration caused by tropomodulin overexpression leads to dilated cardiomyopathy in juvenile mice. J Clin Invest 1998, 101:51-61.
123. Li Y, Huang TT, Carlson EJ, et al. Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase. Nat Genet 1995, 11:376-381.
124. Wang J, Wilhelmsson H, Graff C, et al. Dilated cardiomyopathy and atrioventricular conduction blocks induced by heart-specific inactivation of mitochondrial DNA gene expression. Nat Genet 1999, 21:133-137.
125. Schwartz PJ, Priori SG, Locali EH, et al. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na + channel blockade and to increases in heart rate: Implications for gene-specific therapy. Circulation 1995, 92:3381-3386.
126. Zareba W, Moss AJ, Schwartz PJ, et al. Influence of the genotype on the clinical course of the long QT syndrome. N Engl J Med 1998, 339:960-965.
127. Risch NJ Searching for genetic determinants in the new millennium. Nature 2000, 405:847-856.
128. Rubin EM, Tall A Perspectives for vascular genomics. Nature 2000, 407:265-269.
129. Pennisi E Genomics comes of age. Science 2000, 290:2220-2221.
130. Vukmirovic OG, Tilghman SM Exploring genome space. Nature 2000, 405:820-822.
131. Hwang DM, Fung YW, Wang RX, et al. Analysis of expressed sequence tags from a fetal human heart cDNA library. Genomics 1995, 30:293-298.
132. Matsubara K, Okubo K cDNA analyses in the human genome project. Gene 1993, 135:265-274.
133. Hwang DM, Dempsey AA, Lee CY, et al. Identification of differentially expressed genes in cardiac hypertrophy by analysis of expressed sequence tags. Genomics 2000, 66:1-14.
134. Vogel F Moderne Probleme der Humangenetik. Ergab inn Med Kinderheilkd 1959, 12:52-125.
135. Kalow W Familial incidence of low pseudocholinesterase level. Lancet 1956, 2:576.
136. Hughes HB, Biehl J, Jones AP, et al. Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis. Am Rev Tuberc 1954, 70:266.
137. Evans DAP, Manley KA, McKusic VA Genetic control of isoniazid in man. Br Med J 1960, 2:485.
138. Mahgoub A, Idle JR, Dring LG, et al. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977, 2:584-586.
139. Eichelbaum M, Spannbrucker N, Steincke B, et al. Defective N-oxidation of sparteine in man: A new pharmacogenetic defect. Eur J Clin Pharm 1979, 16:183-197.
140. Weber WW Pharmacogenetics 1997, Oxford University Press, New York.
141. Roden DM Pharmacogenetics and drug-induced arrhythmias. Cardiovasc Res 2001, 50:224-231.
142. Lazarou J, Pomeranz BH, Corey PN Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA 1998, 279:1200-1205.
143. Kalow W Pharmacogenetics in biological perspective. Pharmacol Rev 1997, 49:369-379.
144. Nelson DR, Koymans L, Kamataki T, et al. P450 Superfamily: Update on new sequences gene mapping accession numbers and nomenclature. Pharmacogenetics 1996, 6:1-42.
145. Nakagawa K, Ishizaki T Therapeutic relevance of pharmacogenetic factors in cardiovascular medicine. Pharmacol Ther 2000, 86:1-28.
146. Meyer UA Pharmacogenetics and adverse drug reactions. Lancet 2000, 356:1667-1671.
147. Wolf CR, Smith G Pharmacogenetics. Br Med Bull 1999, 55:367-384.
148. Aithal GP, Day CP, Kesteven PJL, et al. Association of polymorphisms in the cytochrome P450 CYP 2C9 with warfarin dose requirement and the risk of bleeding complications. Lancet 1999, 353:717-719.
149. Takashi H, Echizen H Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet 2001, 40:587-603.
150. Heim M, Meyer UA Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 1990, 336:529-532.
151. Wolf CR, Smith G, Smith RL Science, medicine and the future: Pharmacogenetics. Br Med J 2000, 320:987-990.
152. Kircheiner J, Brosen K, Dahl ML, et al. CYP2D6 and CYP2DC19 genotype-based dose recommendations for antidepressants: A first step towards subpopulation-specific dosages. Arch Psych Scand 2001, 104:173-192.
153. Hamilton RA, Kowalsky SF, Wright EM Effect of the acetylator phenotype on amrinone pharmacokinetics. Clin Pharmacol Ther 1986, 40:615-619.
154. Perry HM, Tan EM, Carmody S, et al. Relationship of acetyl transferase activity to antinuclear antibodies and toxic symptoms in hypertensive patients treated with hydralazine. J Lab Clin Med 1970, 76:114-125.
155. Drayer DE, Reidenberg MM Clinical consequences of polymorphic acetylation of basic drugs. Clin Pharmacol Ther 1977, 22:251-258.
156. Henningsen NC, Cederberg A, Hanson A, et al. Effects of long-term treatment with Procain Amide. Acta Med Scand 1975, 198:475-482.
157. Jukema JW Matching treatment to the genetic basis of lipid disorders in patients with coronary artery disease. Heart 1999, 82:126-127.
158. Kuivenhoven JA, Jukema JW, Zwinderman AH, et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. N Engl J Med 1998, 338:86-93.
159. Dullaart RP, Hoogenberg K, Riemens SC, et al. Cholesteryl ester transfer protein gene polymorphism is a determinant of HDL cholesterol and of the lipoprotein response to a lipid-lowering diet in type 1 diabetes. Diabetes 1997, 46:2082-2087.
160. McNamara DM, Holubkov R, Janosko K, et al. Pharmacogenic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. Circulation 2001, 103:1644-1648.
161. Ferrari P, Bianchi G Genetic mapping and tailored antihypertensive therapy. Cardiovasc Drugs Ther 2000, 14:387-395.
162. Dickerson JE, Hingorani AD, Ashby MJ, et al. Optimisation of anti-hypertensive treatment by crossover rotation of four major classes. Lancet 1999, 353:2008-2013.
163. Pratt RE, Dzau VJ Genomics and hypertension. Hypertension 1999, 33:238-247.
164. Hamet P Genes and hypertension: Where we are and where we should go. Clin Exp Hypertens 1999, 21:947-960.
165. Jeunemaitre X, Soubrier F, Kotelevtsev, et al. Molecular basis of human hypertension. Cell 1992, 71:169.
166. Schunkert H, Hense HW, Gimenez-Roqueplo AP, et al. The angiotensinogen T235 variant and the use of antihypertensive drugs in a population-based cohort. Hypertension 1997, 29:628-633.
167. Hingorani AD, Jia H, Stevens PA, et al. Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition. J Hypertens 1995, 13:1602-1609.
168. Dudley C, Keavney B, Casadei B, et al. Prediction of patient responses to antihypertensive drugs using genetic polymorphisms: Investigation of renin-angiotensin system genes. J Hypertens 1996, 14:259-262.
169. O'Toole L, Stewart M, Padfield P, et al. Effect of the insertion/deletion polymorphism of the angiotensin-converting enzyme gene on response to angiotensin-converting enzyme inhibitors in patients with heart failure. J Cardiovasc Pharmacol 1998, 32:988-994.
170. Hunt SC, Geleijnse JM, Wu LL, et al. Enhanced blood pressure response to mild sodium reduction in subjects with the 235T variant of the angiotensinogen gene. Am J Hypertens 1999, 12:460-466.
171. Ferrari P, Bianchi G Genomics of cardiovascular disorders. Drugs 2000, 59:1025-1042.
172. Bianchi G, Tripodi G, Casari G, et al. Two point mutations within the adducin genes are involved in blood pressure variation. Proc Natl Acad Sci USA 1994, 91:3999-4003.
173. Cusi D, Barlassina C, Azzani T, et al. Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension. Lancet 1997, 349:1353-1357.
174. Kato N, Sugiyama T, Nabika T, et al. Lack of association between the alpha-adducin locus and essential hypertension in the Japanese population. Hypertension 1998, 31:730-733.
175. Glorioso N, Manunta P, Filigheddu F The role of alpha-adducin polymorphism in blood pressure and sodium handling regulation may not be excluded by a negative association study. Hypertension 1999, 34:649-654.
176. Samani NJ Pharmacogenomics of hypertension: A realizable goal?. Clin Sci 2000, 99:231-232.
177. Baker EH, Dong YB, Sagnella GA, et al. Association of hypertension with T594M mutation in beta subunit of epithelial sodium channels in black people resident in London. Lancet 1998, 351:1388-1392.
178. Evans WE, Relling M Pharmacogenomics: Translating functional genomics into rational therapeutics. Science 1999, 286:487-491.
179. Turner ST, Schwartz GL, Chapman AB Antihypertensive pharmacogenetics: Getting the right drug into the right patient. J Hypertens 2001, 19:1-11.
180. The International SNP Map Working Group A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001, 409:928-933.
181. Roses AD Pharmacogenetics and the practice of medicine. Nature 2000, 405:857-865.
182. Roses AD Pharmacogenetics and future drug development and delivery. Lancet 2000, 355:1358-1361.
183. Wilkins MR, Roses AD, Piers CC Pharmacogenomics and the treatment of cardiovascular disease. Heart 2000, 84:353-354.
184. Lindpaintner K Genetics in drug discovery and development: Challenge and promise of individualizing treatment in common complex diseases. Br Med Bull 1999, 55:471-491.
185. Ozdemir V, Shear NH, Kalow W What will be the role of pharmacogenetics in evaluating drug safety and minimizing adverse effects?. Drug Safety 2001, 24:75-85.
186. Nebert DW Pharmacogenetics and pharmacogenomics: Why is this relevant to the clinical geneticist?. Clin Genet 1999, 56:247-258.
187. Brenner S Worms and science: An interview with Sydney Brenner, distinguished research professor at The Salk Institute, La Jolla, USA, and one of the winners of 2002 Nobel Prize for Physiology and Medicine. EMBO Rep 2003, 4:224-226.
188. Brown PO, Botstein D Exploring the new world of the genome with DNA microarrays. Nat Genet 1999, 21:33-37.
189. Cheok MH, Yang W, Pui CH, et al. Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells. Nat Genet 2003, 34:85-90.
190. Chi JT, Chang HY, Wang NN, et al. Genomewide view of gene silencing by small interfering RNAs. Proc Natl Acad Sci USA 2003, 100:6343-6346.
191. Collins FS, Green ED, Guttmacher AE, et al. A vision for the future of genomics research. Nature 2003, 422:835-847.
192. Evans WE, McLeod HL Pharmacogenomics: drug disposition, drug targets, and side effects. N Engl J Med 2003, 348:538-549.
193. Gabriel SB, Schaffner SF, Nguyen H, et al. The structure of haplotype blocks in the human genome. Science 2002, 296:2225-2229.
194. Gilman AG, Simon MI, Bourne HR, et al. Overview of the Alliance for Cellular Signaling. Nature 2002, 420:703-706.
195. Hoffman SL, Subramanian GM, Collins FH, et al. Plasmodium, human and Anopheles genomics and malaria. Nature 2002, 415:702-709.
196. Li J, Ning Y, Hedley W, et al. The molecule pages database. Nature 2002, 420:716-717.
197. Mitsui K, Tokuzawa Y, Itoh H, et al. The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell 2003, 113:631-642.
198. Roses AD Genome-based pharmacogenetics and the pharmaceutical industry. Nat Rev Drug Discov 2002, 1:541-549.
199. Sachidanandam R, Weissman D, Schmidt SC, et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001, 409:928-933.
200. Waterston RH, Lander ES, Sulston JE On the sequencing of the human genome. Proc Natl Acad Sci USA 2002, 99:3712-3716.